温肾活血汤治疗冠心病心绞痛40例

Kidney-warming Blood-activating Decoction in Treating 40 Cases of Coronary Heart Disease Angina Pectoris

目的:观察温肾活血汤治疗冠心病心绞痛的临床价值。方法:将80例冠心病心绞痛患者按就诊的先后顺序随机分为观察组、对照组各40例,2组患者均行对症支持处理,30 mg/次,3次/d。观察组在对照组治疗的基础上服用温肾活血汤,上药每日1剂,水煎早晚分服。2组均连续治疗2周。比较2组干预后氨基末端脑钠肽前体(NT-pro BNP)、基质金属蛋白酶9(MMP-9)、血管内皮素1(ET-1)、一氧化氮(NO)水平,以及左室舒张末期内径(LVEDD),左室收缩末期内径(LVESD)及左室射血分数(LVEF%)。结果:治疗后观察组NT-pro BNP和MMP-9水平均低于对照组,2组间比较差异均有统计学意义(P<0.05)。治疗后观察组ET-1水平低于对照组,NO水平高于对照组,2组间比较差异均有统计学意义(P<0.05)。治疗观察组LVEDD和LVESD低于对照组,LVEF%高于对照组,2组间比较差异均有统计学意义(P<0.05)。结论:针对冠心病心绞痛患者联合使用温肾补血汤治疗,能有效降低心肌损伤,改善心肌功能,延缓心肌重构,提高临床治疗效果。

Objective： To observe clinical values of kidney-warming blood-activating decoction in treating coronary heart disease（CHD） angina pectoris（AP）. Methods： Eighty patients were randomized into the observation group and the control group according to the visiting order, 40 cases each group, both groups accepted symptomatic treatment, 30 mg each time, three times each day. Based on the therapy of the control group accepted, the observation group accepted kidney-warming blood-activating decoction orally, one dose each day, water decoction and taking the decoction in the morning and evening. Both groups were treated for two weeks consecutively. The levels of nitric oxide（NO）, vascular endothelin-1（ET-1）, matrix metalloproteinase-9（MMP-9） and N-terminal brain natriuretic peptide precursor（NT-pro BNP）, left ventricular end diastolic diameter（LVEDD）, left ventricular end systolic diameter（LVESD） and left ventricular ejection fraction（LVEF%） were compared between both groups after the intervention.Results： The observation group was lower than the control group in the levels of NT-pro BNP and MMP-9 after treating,and the difference showed statistical meaning between both groups（P〈0.05）. The observation group was lower than the control group in the levels of ET-1 after treating, higher than the control group in the levels of NO, and the difference had statistical meaning（P 〈0.05）. The observation group was lower than the control group in LVEDD and LVESD after treating, higher than the control group in LVEF%, and the difference was statistically significant（P 〈0.05）. Conclusion： Treating CHD patients with AP by kidney-warming blood-activating decoction could effectively decrease myocardial damage, improve myocardial function, delay myocardial reconstruction and raise therapeutic effects in clinic.